Preparation method and application of CO2 responsive micro-nano drug delivery system

Abstract

The invention relates to a preparation method and application of a CO2 responsive micro-nano drug delivery system, which can effectively achieve the effects of improvement of lung deposition capability, reduction of systemic distribution of drugs, reduction of systemic toxic and side effects, responsive slow release in the lung, and improvement of drug utilization and curative effect. The preparation method comprises the following steps: preparing a polylactic acid-polylysine polymer; dissolving the polylactic acid-polylysine polymer in dimethyl sulfoxide, then adding N, N-dimethylacetamide dimethyl acetal, carrying out a nitrogen protection reaction, dialysis and freeze-drying, dissolving the obtained solution and budesonide in dimethyl sulfoxide, adding ultrapure water, and carrying out dialysis and freeze-drying to obtain PLA-mPLL / BUD nanoparticles; preparing yeast microcapsules, dissolving the PLA-mPLL / BUD nanoparticles in ultrapure water, adding the yeast microcapsules, carrying out vortex uniform mixing, carrying out room temperature incubation, centrifuging, and carrying out freeze drying to obtain the CO2 responsive micro-nano drug delivery system YGM / PLA-mPLL / BUD. The preparation method is simple, raw materials are rich, production and preparation are easy, and the system is a great innovation in medicines for treating asthma, pulmonary fibrosis, chronic pulmonary obstruction pulmonary disease, pneumonia and lung injury.

Description

technical field

[0001] The present invention relates to medicine, especially a CO 2 Preparation method and application of responsive micro-nano drug delivery system. Background technique

[0002] Asthma is a complex chronic respiratory disease, usually accompanied by pathological infiltration of eosinophils, mast cells and T cells (Nature Immunology, 2015, 16: 45). Statistics show that in recent years, the morbidity and mortality of asthma have increased at a rate of 20%-50% per decade (Chinese Medical Journal, 2018, 98: 1453). Glucocorticoids are currently the first choice for the clinical treatment of asthma. They can effectively fight against allergic inflammation, reduce airway hyperresponsiveness, and improve lung function, but the therapeutic effect is not very satisfactory, and long-term inhalation will cause some systemic side effects (Seminars in Immunology , 2019, 46:101294). Therefore, how to selectively target the drug to the alveoli, release the anti-inflamma...